The effect of ergometrine on breast feeding.
A randomised, controlled trial of 1429 women was carried out to compare 'active' management of the third stage of labour, using i.v. Ergometrine 0.5 mgs, with a method of 'physiological' management, in women at 'low risk' to haemorrhage. A separate sub-study, with 168 women in each of the two groups, examined the possible effects of Ergometrine on serum prolactin levels and the duration of breast feeding. No difference was found in peak (post-suckling) serum prolactin levels taken from 126 women between 48 and 72 hours postnatal. Further studies with larger sample sizes would give a more dependable result. Women who did not receive the drug Ergometrine were more likely to continue breast feeding for longer than four weeks than those who did (p less than 0.05). It is recommended that this drug should not be given routinely to women intending to breast feed.
C M
CM
Begley
D001942:Breast Feeding; D004874:Ergonovine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007749:Labor Stage, Third / Q000187:drug effects; D007774:Lactation / Q000187:drug effects; D049590:Postpartum Period / Q000187:drug effects; D011247:Pregnancy; D011256:Pregnancy Outcome; D011388:Prolactin / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
D011388:Prolactin; D004874:Ergonovine